FDA enforcement actions against AI medical devices expose a critical gap: standard application logs cannot prove what an algorithm did at a specific point in ti
FDA enforcement actions against AI/ML-based medical devices are accelerating. As more Software as a Medical Device (SaMD) products reach the market, FDA investigators are encountering a new challenge: how to audit an algorithm that changes over time. Traditional medical device inspections focus on physical manufacturing processes, design history files, and complaint handling. AI devices introduce a fundamentally different problem. The "product" is a mathematical model that may have been updated dozens of times since its initial clearance.
When FDA issues a Form 483 observation or warning letter against an AI medical device, the manufacturer must demonstrate exactly which version of the algorithm was running at any given time, what validation testing was performed on that version, how the model was updated and whether those updates followed the approved change control plan, and what the algorithm actually did for specific patients or clinical scenarios under investigation. Most AI device manufacturers cannot answer these questions with verifiable evidence.
The standard approach to AI auditability relies on application-layer logging: database records, server logs, and version control systems. These mechanisms share a fundamental problem that FDA investigators understand well. They are mutable. A database record can be updated after the fact. A log file can be edited. A git history can be rebased. Even if a manufacturer has no intent to alter records, the mere possibility of alteration undermines the evidentiary value of the entire audit trail.
FDA investigators are trained to evaluate record integrity. When they encounter audit systems that depend on application-layer trust, they ask a straightforward question: what prevents these records from being modified after the event they describe? For most AI device manufacturers, the honest answer is organizational policy and access controls. But policy is not proof. Access controls demonstrate intent, not tamper-evidence. In an enforcement context where patient safety is at stake, this distinction matters enormously.
Cryptographic decision records solve this problem at the infrastructure level. Instead of relying on organizational controls to prevent record alteration, each AI inference generates a signed record at the moment of decision. The record includes a hash of the model binary, the confidence score, the input data fingerprint, the active policy version, and the resulting decision action. These records are sealed with device-bound cryptographic keys before any network transmission, creating evidence that cannot be fabricated or backdated.
For FDA enforcement scenarios, this means investigators can verify exactly which algorithm version produced a specific clinical output, confirm that the model version matches the version documented in the cleared submission, trace every model update through a tamper-evident chain, and validate that confidence thresholds and escalation policies were enforced as documented. This level of verifiability transforms FDA interactions from adversarial document requests into straightforward evidence reviews.
The time to implement cryptographic decision records is before an enforcement action begins. Retrofitting audit infrastructure during an active investigation is both technically difficult and strategically disadvantageous. Organizations that deploy decision integrity infrastructure proactively demonstrate a commitment to quality and transparency that FDA recognizes. Those that scramble to produce records during an investigation face skepticism about the provenance and completeness of whatever evidence they can assemble.
For AI medical device manufacturers, the question is not whether FDA will ask for verifiable evidence of algorithm behavior. The question is whether you will have it when they do.